Stephanie Alimena

Stephanie Alimena

Auto-generated profile, based on publicly available information

Stephanie Alimena

Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
SAStephanie Alimena
Stephanie Alimena
DYDavid D. Yang
David D. Yang
AMAlexander Melamed
Alexander Melamed
BMBrandon A. Mahal
Brandon A. Mahal
MWMichael J. Worley
Michael J. Worley
MKMartin King
Martin King

9 June 2022 in Current Problems in Cancer
Verified
Journal Article
Closed access
SAStephanie Alimena
Stephanie Alimena
JDJoshua Davis
Joshua Davis
RFRaina N. Fichorova
Raina N. Fichorova
SFSarah Feldman
Sarah Feldman

1 July 2021 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
SAStephanie Alimena
Stephanie Alimena
SPSuvidya Lakshmi Pachigolla
Suvidya Lakshmi Pachigolla
SFSarah Feldman
Sarah Feldman
DYDavid Yang
David Yang
POPeter F. Orio
Peter F. Orio
MKMartin King
Martin King
Background: Although the incidence of cervical cancer among younger Black women is now equivalent to that of White women, it is unknown whether the reduced incidence has affected survival rates among younger Black women. The goal of this study was to assess differences in survival by age and race. Patients and Methods: A retrospective cohort study was performed using the National Cancer Database to analyze women with nonmetastatic cervical cancer diagnosed between 2004 and 2014. Women with unknown survival data and those who died within 3 months of diagnosis were excluded. Multivariable logistic regression models evaluated interactions between age and race (Black vs non-Black) for presentation with stage I disease and receipt of optimal treatment. A multivariable Cox regression model was used to evaluate survival differences by age and race. Results: Of 55,659 women included, 16.4% were Black. Compared with their non-Black counterparts, fewer Black women presented with stage I disease (37.8% vs 47.8%; P<.01) and received optimal treatment (46.2% vs 58.3%; P<.01). Fewer Black women had private insurance if they were aged <65 years (39.6% vs 55.7%; P<.01), but not if they were aged ≥65 years (11.7% vs 12.4%; P=.43). According to multivariable logistic regression, Black women aged ≤39 years were less likely to present with stage I disease, with a significant interaction term between age and race (P<.01 for interaction). Disparities in overall survival by race were greatest for Black women aged ≤39 years (adjusted hazard ratio, 1.32; 95% CI, 1.20–1.46; P<.01) but decreased with increasing age interval until no disparity was noted for women aged ≥65 years (P<.01 for interaction). Conclusions: Younger Black women with cervical cancer are at risk for presenting with higher-stage disease and having worse overall survival. These findings may be related to insurance-related disparities and inadequate follow-up for abnormal Papanicolaou test results. Younger Black women with cervical cancer may be a particularly vulnerable population.

1 April 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
BMBeryl L. Manning-Geist
Beryl L. Manning-Geist
SAStephanie Alimena
Stephanie Alimena
MCMarcela G. del Carmen
Marcela G. del Carmen
AGAnnekathryn Goodman
Annekathryn Goodman
RCRachel M. Clark
Rachel M. Clark
MWMichael J. Worley
Michael J. Worley

22 February 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
SAStephanie Alimena
Stephanie Alimena
BSBriana Joy K. Stephenson
Briana Joy K. Stephenson
JWJames W. Webber
James W. Webber
LWLaura Wollborn
Laura Wollborn
CSChad B. Sussman
Chad B. Sussman
KEKevin M Elias
Kevin M Elias
Serum miRNAs are promising biomarkers for several clinical conditions, including ovarian cancer. To inform equitable implementation of these tests, we investigated the effects of race, ethnicity, and socioeconomic status on serum miRNA profiles. Serum samples from a large institutional biobank were analyzed using a custom panel of 179 miRNA species highly expressed in human serum, measured using the Abcam Fireplex assay via flow cytometry. Data were log-transformed prior to analysis. Differences in miRNA by race and ethnicity were assessed using logistic regression. Pairwise t tests analyzed racial and ethnic differences among eight miRNAs previously associated with ovarian cancer risk. Pearson correlations determined the relationship between mean miRNA expression and the social deprivation index (SDI) for Massachusetts residents. Of 1,586 patients (76.9% white, non-Hispanic), compared with white, non-Hispanic patients, those from other racial and ethnic groups were younger (41.9 years ± 13.2 vs. 51.3 ± 15.1, P < 0.01) and had fewer comorbidities (3.5 comorbidities ± 2.7 vs. 4.6 ± 2.8, P < 0.01). On logistic regression, miRNAs predicted race and ethnicity at an AUC of 0.69 (95% confidence interval, 0.66–0.72), which remained consistent when stratified by most comorbidities. Among eight miRNAs previously associated with ovarian cancer risk, seven significantly varied by race and ethnicity (all P < 0.01). There were no significant differences in SDI for any of these eight miRNAs. miRNA expression is significantly influenced by race and ethnicity, which remained consistent after controlling for confounders. Understanding baseline differences in biomarker test characteristics prior to clinical implementation is essential to ensure instruments perform comparably across diverse populations. Prevention Relevance: This study aimed to understand factors affecting miRNA expression, to ensure we create equitable screening tests for ovarian cancer that perform well in diverse populations. The goal is to ensure that we are detecting ovarian cancer cases earlier (secondary prevention) in women of all races, ethnic backgrounds, and socioeconomic means.

1 January 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
SAStephanie Alimena
Stephanie Alimena
MSMackenzie W. Sullivan
Mackenzie W. Sullivan
LPLauren Philp
Lauren Philp
KDKatelyn Dorney
Katelyn Dorney
HHHarrison Hubbell
Harrison Hubbell
RSRachel Clark Sisodia
Rachel Clark Sisodia